A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Status:
Completed
Trial end date:
2021-01-06
Target enrollment:
Participant gender:
Summary
This study is known as a "drug interaction study" and is being done to see how abemaciclib
may affect the blood levels of a drug mixture of commonly used drugs (caffeine, warfarin,
dextromethorphan, and midazolam) when taken in combination with abemaciclib. Each participant
will complete screening and four study periods, with the option to continue to receive
abemaciclib in a safety extension phase. All participants will complete a safety follow-up.